» Articles » PMID: 37209390

Inflammatory and Infectious Disorders in Endocrine Pathology

Overview
Journal Endocr Pathol
Specialties Endocrinology
Pathology
Date 2023 May 20
PMID 37209390
Authors
Affiliations
Soon will be listed here.
Abstract

A variety of inflammatory conditions may directly involve the endocrine glands, leading to endocrine dysfunction that can cause severe consequences on patients' health, if left untreated. Inflammation of the endocrine system may be caused by either infectious agents or other mechanisms, including autoimmune and other immune-mediated processes. Not infrequently, inflammatory and infectious diseases may appear as tumor-like lesions of endocrine organs and simulate neoplastic processes. These diseases may be clinically under-recognized and not infrequently the diagnosis is suggested on pathological samples. Thus, the pathologist should be aware of the basic principles of their pathogenesis, as well as of their morphological features, clinicopathological correlates, and differential diagnosis. Interestingly, several systemic inflammatory conditions show a peculiar tropism to the endocrine system as a whole. In turn, organ-specific inflammatory disorders are observed in endocrine glands. This review will focus on the morphological aspects and clinicopathological features of infectious diseases, autoimmune disorders, drug-induced inflammatory reactions, IgG4-related disease, and other inflammatory disorders involving the endocrine system. A mixed entity-based and organ-based approach will be used, with the aim to provide the practicing pathologist with a comprehensive and practical guide to the diagnosis of infectious and inflammatory disorders of the endocrine system.

Citing Articles

Association of modifiable risk factors and infectious diseases among individuals with hypertension: a prospective cohort study.

Hu N, Ai B, Wang Y, Ren Y, Chen H, Chen Z BMC Infect Dis. 2024; 24(1):1162.

PMID: 39407144 PMC: 11481595. DOI: 10.1186/s12879-024-10064-1.


PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms: exploring their potential role as theragnostic and prognostic biomarkers.

Multone E, La Rosa S, Sempoux C, Uccella S Virchows Arch. 2024; 485(5):841-851.

PMID: 38771338 PMC: 11564274. DOI: 10.1007/s00428-024-03825-5.


Effect of Caffeine on the Inflammatory-Dependent Changes in the GnRH/LH Secretion in a Female Sheep Model.

Herman A, Tomczyk M, Wojcik M, Bochenek J, Antushevich H, Herman A Int J Mol Sci. 2024; 25(5).

PMID: 38473910 PMC: 10932312. DOI: 10.3390/ijms25052663.


Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?.

Uccella S Endocr Pathol. 2024; 35(2):91-106.

PMID: 38470548 PMC: 11176254. DOI: 10.1007/s12022-024-09807-2.


Therapeutic Uses of Rituximab and Clinical Features in Immunoglobulin G4-Related Disease: A Systematic Review.

Patel U, Saxena A, Patel D, Ayesha I, Monson N, Klair N Cureus. 2023; 15(9):e45044.

PMID: 37701160 PMC: 10494991. DOI: 10.7759/cureus.45044.

References
1.
Straub R . Interaction of the endocrine system with inflammation: a function of energy and volume regulation. Arthritis Res Ther. 2014; 16(1):203. PMC: 3978663. DOI: 10.1186/ar4484. View

2.
Korem Kohanim Y, Tendler A, Mayo A, Friedman N, Alon U . Endocrine Autoimmune Disease as a Fragility of Immune Surveillance against Hypersecreting Mutants. Immunity. 2020; 52(5):872-884.e5. PMC: 7237888. DOI: 10.1016/j.immuni.2020.04.022. View

3.
Ryder M, Callahan M, Postow M, Wolchok J, Fagin J . Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014; 21(2):371-81. PMC: 4573438. DOI: 10.1530/ERC-13-0499. View

4.
Percik R, Shoenfeld Y . Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?. Best Pract Res Clin Endocrinol Metab. 2020; 34(1):101411. DOI: 10.1016/j.beem.2020.101411. View

5.
Wright J, Powers A, Johnson D . Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021; 17(7):389-399. PMC: 8769055. DOI: 10.1038/s41574-021-00484-3. View